模拟目标试验:革兰阴性菌血症短期与长期抗生素治疗的比较
该研究采用克隆-删失-加权方法模拟目标试验,纳入哥本哈根四家医院2018至2021年1040例革兰阴性菌血症患者,比较短期(5-7天)与长期(8-14天)抗生素治疗。调整后90天全因死亡风险差1.3%(95%CI:-0.7,3.3),风险比1.12(95%CI:0.89,1.37);复发风险差0.7%(95%CI:-2.3,3.8),风险比1.07(95%CI:0.71,1.45)。结论为短期与长期治疗结局相当。
要点
- 模拟目标试验显示革兰阴性菌血症短期与长期抗生素治疗90天死亡风险无显著差异。
- 调整后90天全因死亡风险比1.12(95%CI:0.89,1.37),复发风险比1.07(95%CI:0.71,1.45)。
- 队列中86%为社区获得性感染,78%感染源为尿路,73%病原体为大肠埃希菌。
核心结论
- 在革兰阴性菌血症患者中,短期与长期抗生素治疗相比,结局相当。
研究设计与样本
- 采用克隆、删失和加权方法模拟目标试验,将革兰阴性菌血症患者分配至短期(5-7天)或长期(8-14天)抗生素治疗。
- 模拟试验纳入哥本哈根四家医院2018年至2021年的患者,共1040例。
- 主要结局为90天全因死亡,次要结局为临床和微生物学复发的复合终点。
主要发现
- 队列中位年龄76岁,男性占54%,社区获得性革兰阴性菌血症占86%,尿路感染源占78%,大肠埃希菌病原体占73%。
- 调整后90天全因死亡风险差为1.3%(95%CI:-0.7,3.3),风险比为1.12(95%CI:0.89,1.37)。
- 调整后90天复发风险差为0.7%(95%CI:-2.3,3.8),风险比为1.07(95%CI:0.71,1.45)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite the availability of antimicrobial therapies, gram-negative bacteremia remains a significant cause of morbidity and mortality on a global level. Recent randomized controlled trials support shorter antibiotic treatment duration for individuals with uncomplicated gram-negative bacteremia. The target trial framework using the cloning approach utilizes real-world data but eliminates the issue of immortal time bias seen in observational studies by emulating the analysis of randomized trials with full adherence. METHOD: A hypothetical target trial allocating individuals with gram-negative bacteremia to either short antibiotic treatment duration (5-7 days) or longer antibiotic treatment duration (8-14 days) was specified and emulated using the cloning, censoring, and weighting approach. The primary outcome was 90-day all-cause mortality. Secondary outcome was a composite endpoint of clinical and microbiological relapse. The emulated trial included individuals from four hospitals in Copenhagen from 2018 through 2021. RESULTS: In sum, 1040 individuals were included. The median age of the cohort was 76 years, the majority were male (54%), had community-acquired gram-negative bacteremia (86%), urinary tract infection as the source of the infection (78%), and Escherichia coli as the pathogen of the infection (73%). The adjusted 90-day risk difference in all-cause mortality was 1.3% (95% confidence interval [CI]: -.7, 3.3), and the risk ratio was 1.12 (95% CI: .89, 1.37). The adjusted 90-day risk difference in relapse was 0.7% (95% CI: -2.3, 3.8), and the risk ratio was 1.07 (95% CI: .71, 1.45). CONCLUSIONS: We found comparative outcomes for shorter treatment duration compared to longer treatment duration in patients with gram-negative bacteremia.
引用
- Tingsgård S, Bastrup Israelsen S, Østergaard C, et al. Emulating a Target Trial of Shorter Compared to Longer Course of Antibiotic Therapy for Gram-Negative Bacteremia. Clin Infect Dis. 2024. PMID: 37949816. doi:10.1093/cid/ciad670
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。